Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01874054 · ClinicalTrials.gov registry record · Phase 1
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01874054 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 55 participants.
The verdict
NCT01874054, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.
Interventions
- DRUG brentuximab vedotin
- DRUG bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-06 |
| Est. Completion | 2018-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01874054
The ClinicalTrials.gov registry entry for NCT01874054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which brentuximab vedotin is the first listed.
NCT01874054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01874054 about?
NCT01874054 is a clinical study titled "Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma". The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentux...
What is the current status of trial NCT01874054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2013-06. Estimated completion is 2018-02-20.
What interventions are being tested in trial NCT01874054?
The interventions under investigation include: brentuximab vedotin (DRUG), bendamustine (DRUG).
Who is sponsoring clinical trial NCT01874054?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.